Thus, an increased NRF2 expression/activity can represent a potential mechanism of resistance to pro-oxidant therapy since NRF2 can reduce 4-Hydroxynonenal sensitivity in prostate cancer cells. Here, NFE2L2 is linked to Familial prostate cancer.